Publications by authors named "Irina Sidina"
Purpose: Therapy targeting CTLA-4 immune checkpoint provides increased survival in patients with advanced melanoma. However, immunotherapy is frequently associated with delayed and heterogeneous clinical responses and it is important to identify prognostic immunological correlates of clinical endpoints.
Experimental Design: 77 patients with stage III/IV melanoma were treated with ipilimumab alone every 3 weeks, during 9 weeks.
Article Synopsis
- Ipilimumab, an antibody approved for treating metastatic melanoma in Europe, was studied in a retrospective analysis involving patients with advanced melanoma previously treated with chemotherapy.
- The study included 45 patients, revealing a 13% best overall response rate and a median overall survival of 8 months, with brain metastases not significantly impacting survival outcomes.
- Factors like baseline corticosteroid use and high LDH levels negatively affected overall survival, indicating that certain patient subsets may benefit more from ipilimumab treatment.
Article Synopsis
- * The study found that overall response rates were 53%, with a median overall survival (OS) of 7.5 months and progression-free survival (PFS) of 3.6 months, even among patients with brain metastases, who had a 50% response rate.
- * Common side effects included fatigue, joint pain, and skin issues, with 16% of patients developing squamous cell carcinoma; however, the toxicity was deemed manageable, confirming the drug